Pretax income is the income that a company earns before paying income taxes. Aquestive Therapeutics's pretax income for the
three
months ended in Sep. 2024 was $-11.51 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-35.09 Mil.
Aquestive Therapeutics's pretax margin was -84.99%.
During the past 8 years, Aquestive Therapeutics's highest Pretax Margin was -13.36%. The lowest was -138.77%. And the median was -102.57%.
Aquestive Therapeutics Pre-Tax Income Historical Data
The historical data trend for Aquestive Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Pre-Tax Income falls into.
Aquestive Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Aquestive Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics (NAS:AQST) Pre-Tax Income Explanation
Aquestive Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 8 years, Aquestive Therapeutics's highest Pretax Margin was -13.36%. The lowest was -138.77%. And the median was -102.57%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aquestive Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 